We conducted a phase I/II trial, to evaluate the efficacy and safety of an intravenous liposomal formulation of busulphan (LBu) as a myeloablative agent for stem cell transplantation (SCT). The liposomal busulphan was administered as a 3 h infusion twice daily over 4 consecutive days. Six adults received 1.6-2 mg/kg/dose and 18 children received 1.8-3 mg/kg/dose. Pharmacokinetic parameters were studied after the first and the last dose of busulphan. No significant difference in clearance, AUC, elimination half-lives or distribution volume between the first and the last dose was found in either groups. A significantly (P Ͻ 0.005) higher clearance was observed in children after the first and the last dose (3.61 and 3.79 ml/min/kg, respectively) compared to adults (2.40 and 2.33 ml/min/kg, respectively). The elimination half-lives after the first and the last dose were significantly (P Ͻ 0.005) shorter in children (2.59 and 2.72 h, respectively) compared to adults (3.35 and 3.61 h, respectively). Clearance correlated significantly with age. However, no significant correlation with age was observed when clearance was adjusted to the body surface area. Two cases of VOD following a total dose of 24 mg/kg were observed. Six patients experienced mucositis. No other organ toxicity was observed. We conclude that intravenous liposomal busulphan pharmacokinetics is age dependent. A dosage schedule based on body surface area should be used especially in young children to reduce the age-dependent difference in kinetics. An intravenous liposomal dose of busulphan of 500 mg/m 2 is suggested to reach a similar systemic exposure and myeloablative effect in both children and adults. Moreover, the novel liposomal form of busulphan showed a favorable toxicity profile and seems safe as a part of the high-dose therapy prior to SCT.
Stem cell transplantation (SCT) using myeloablative conditioning with busulphan and cyclophosphamide (BuCy) is a curative treatment for both hematological malignancies and non-malignant disorders. [1] [2] [3] [4] [5] Busulphan was introduced as an alternative to total body irradiation (TBI) especially in young patients to avoid the late adverse effects following TBI. 6 The therapeutic efficacy for BuCy was shown to be equivalent if not superior to cyclophosphamide and TBI for certain diagnoses such as AML, CML and MDS. 7, 8 The maximum tolerable dose of busulphan was established to be 16 mg/kg given over 4 consecutive days. 5 During the last decade the pharmacokinetics of busulphan have been extensively studied in adults and children, aiming to define the therapeutic window. After a total dose of busulphan of 16 mg/kg, lower plasma concentrations, minimal toxicity and higher rates of graft failure have been reported in children compared to adults. Many studies have shown a high inter-and intra-patient variability in kinetics. Circadian rhythmicity, age, drug interactions, bioavailability, liver status and disease have been identified as factors underlying the observed inter-patient variability. [9] [10] [11] [12] [13] [14] Bioavailability of the drug was shown to vary six-fold in children and about two-fold in adults. 15 Several investigators have suggested that young children may benefit from a higher systemic exposure and better antitumor effect after a busulphan dosage based on body surface area. 9, 10, 16, 17 Some authors have proposed that age-dependent pharmacokinetics of busulphan may be explained by a higher metabolic rate of busulphan during the first pass effect in children. 18, 19 Thus, an intravenous formulation of busulphan was thought to decrease age-dependent variability of pharmacokinetics and to optimize high-dose therapy prior to SCT. Recently, four different intravenous formulations of busulphan were presented aiming to reduce the risk of treatment-related complications by better prediction of drug exposure. [20] [21] [22] [23] However, the pharmacokinetics of these formulations have not yet been investigated in pediatric patients. The aims of the present study were to investigate the safety of high-dose liposomal busulphan administered intravenously as a myeloablative treatment prior to SCT, to investigate the pharmacokinetics in relation to age, and to define an optimal dosage of intravenous liposomal busulphan. The present phase I-II trial has shown that liposomal busulphan can be safely used as a high-dose treatment in pediatric and adult patients. For the first time, pharmacokinetics of intravenously administered busulphan have been shown to be age-dependent; 500 mg/m 2 is suggested to be an optimal dose of liposomal busulphan for intravenous administration.
Patients and methods

Preparation of liposomal busulphan
Liposomal busulphan was prepared as described previously. 24 Briefly, lipids (L-␣-phosphatidylcholine, 1,2-dioleolyl-sn-glycero-3-phosphate and cholesterol) were dissolved in chloroform. Busulphan was added. The mixture of lipids and busulphan was dried by evaporation to a thin film coating the inside of a round glass vessel. Any traces of solvent were removed under a gentle stream of nitrogen. The mixture was then hydrated with glucose (50 mg/ml). Multilamellar vesicles were formed by vortexing the lipidaqueous mixture. The suspension was transferred to an extruder (Holder with 2 liter capacity, AKA filter, Göt-tingen, Germany) and extruded five times under nitrogen pressure through two stacked polycarbonate filters with a pore size of 100 nm. The solution was filtered through a Millex filter (0.22 mm, Millipore GV, Bedford, MA, USA) and was pyrogen free and sterile. Busulphan concentrations were measured before and after filtration to determine the entrapment efficiency. The busulphan concentration was 0.23 Ϯ 0.03 mg/ml (mean Ϯ s.d.). Liposomal busulphan was prepared freshly for each patient.
Patients
Between October 1997 and February 2001 a total of 24 patients were enrolled in the study. Eighteen children with a median age of 1.3 years (range 0.4-11.5 years) and six adults with a median age of 47 years (range 33.6-55 years) participated. Four children had Hurler's syndrome (MPS type IH), five had acute myeloid leukemia, one had sickle cell disease, one had familial hemophagocytic lymphohistiocytosis (FHL), one had severe combined immunodeficiency (SCID), one acute lymphoid leukemia, one myelodysplastic syndrome (MDS), one a relapsed chronic myeloid leukemia, one Wiskott-Aldrich syndrome and two had chronic myelomonocytic leukemia (CMML). The adult group included three patients with acute myeloid leukemia and three patients with chronic myeloid leukemia. Clinical characteristics of the patients are summarized in Tables 1  and 2 . All children and three adults underwent allogeneic stem cell transplantation, while three adult patients underwent autologous stem cell transplantation.
Treatment
The conditioning regimen consisted of liposomal busulphan and cyclophosphamide. Two children with CMML received additional treatment with melphalan (140 mg/m 2 ). Liposomal busulphan was administered twice daily. All children and three adult patients received in total eight doses over 4 days and three adult patients received four doses over 2 days followed by oral busulphan for the next 2 days. All patients received about 2 mg/kg, except for one child (Ch4) who received 1 mg/kg according to the treatment protocol. The first dose was calculated on the basis of BSA being 560 Ϯ 40 mg/m 2 for adults and 432 Ϯ 81 mg/m 2 for children. To minimize the risk of chronopharmacologic variation, busulphan was given at 8.00 am and 8.00 pm. Liposomal busulphan was administered as a 2 h infusion for adults and 3 h infusion for children.
Clonazepam (1.5 mg/ day on days 1 and 2, and 3 mg/day on days 3 and 4 for adults, 0.3 mg/day for 2 days followed by 0.6 mg for the next 2 days for children) was given to all patients as prophylaxis against seizures. All patients undergoing allogeneic stem cell transplantation received methotrexate and cyclosporine as graft-versus-host disease (GVHD) prophylaxis. 25 Methotrexate was administered on days +1, +3, +6 and +11 at a dose of 15, 10, 10 and 10 mg/m 2 , respectively. Cyclosporine was given at either 3 mg/kg or 5 mg/kg on day Ϫ1 followed by 1 mg/kg or 3 mg/kg, respectively, from day 0 with the aim of keeping therapeutic concentrations between 100 and 300 ng/ml depending on the donor type. The study was approved by the ethics committees at the Karolinska Institutet and University Children's Hospital in Zurich and by the Swedish Medical Products Agency. Adult patients and parents of the children were informed and gave consent to the study.
Pharmacokinetics
Blood samples were collected in heparinized tubes before infusion, 15 and 30 min after starting the infusion, at the end of infusion and at 3, 5, 15, 30, 60, 120, 180, 240, 360, 480 and 600 min after the end of infusion. Plasma was immediately separated and stored at Ϫ20°C until assayed. Plasma samples were thawed before analysis. The appropriate plasma volume (0.5-1 ml) was transferred to new tubes and sodium iodide (1 ml, 8M), internal standard (1,5-bis(methanesulfonoxy) pentane; 500 ng in 50 l acetone) and n-heptane (0.4 ml) were added. Busulphan and the internal standard were reacted with sodium iodide for 45 min at 70°C with gentle stirring to form 1,4-diiodobutane and 1,5-diiodopentane. The heptane phase was taken for analysis using a gas chromatography with electron capture Auto = autologous stem cell transplantation; Allo = allogeneic stem cell transplantation; Outcome (days) = days of surviving post SCT. All patients received allogeneic stem cell transplantation. Outcome (days) = days of surviving post SCT; Re-SCT = patient was retransplanted 100 days after the first transplantation; VOD I = mild veno-occlusive disease; VOD II = moderate veno-occlusive disease; BuCy = busulphan and cyclophosphamide; Bu Mel Cy = busulphan, melphalan and cyclophosphamide; MPS type IH = Hurler's disease.
detection as described previously. 26 The calibration curve using spiked plasma was linear within the range 10-2600 ng/ml. Busulphan concentrations were calculated using Star integration program (Varian, Walnut Creek, CA, USA).
Busulphan concentration-time data were adjusted to a two-compartment open model using Gauss-Newton (Levenberg-Hartly) criteria. Parameters such as distribution volume of the central compartment, elimination rate constant, maximum plasma concentration and microconstants were estimated. The clearance (Cl) and distribution volume in steady-state were calculated from the primary parameters. The plasma concentrations vs time curves (AUC) were calculated from the model-derived parameters and the elimination half-lives were calculated from the slope of the terminal phase of elimination.
Pharmacokinetic modeling was performed using WinNonlin version 3.0 (Pharsight, Mountain View, CA, USA). The mean, median and standard deviations were calculated using GraphPad, InStat (version 3.0, Graph Pad, San Diego, CA, USA). All values are presented as mean Ϯ s.d. StatistiBone Marrow Transplantation cal analysis was performed using the Kruskal-Wallis test (non-parametric ANOVA) and Mann-Whitney U test (nonparametric, unpaired, two-tailed) whenever appropriate.
Diagnosis of VOD, mucositis and GVHD, including scoring of severity
Veno-occlusive disease (VOD) was diagnosed on the basis of clinical criteria, ie presence of hyperbilirubinemia (total serum bilirubin Ͼ34 mol/l) and development of two of the following signs during the first 21 days post transplant: weight gain Ͼ5% from preconditioning baseline weight, ascites and/or hepatomegaly. VOD severity was graded as mild (self-limited and requiring no treatment), moderate (clinical abnormalities which required pain control and/or diuretics for fluid retention) and severe VOD (clinical abnormalities which required therapy and did not resolve by day 100 post transplant or ended in death). Mucositis was scored (I, II and III), according to Bearman et al. 27 Diagnosis and clinical grading of GVHD were based on Glucksberg et al criteria. 28 
Results
Clinical outcome
Clinical outcomes are shown in Tables 1 and 2 . All patients became neutropenic following the administration of liposomal busulphan and cyclophosphamide with or without melphalan. The median time to neutrophil engraftment (Ͼ0.5 ϫ 10 9 /l) was 11 days (range 9-21) for the children and 14 days (range [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] for the adults. The median time to platelet recovery of Ͼ20 ϫ 10 9 /l and Ͼ50 ϫ 10 9 /l was 15 days (range 3-32) and 28 days (range 3-86), respectively. Both children with CMML died within 6 months of transplantation. One child died because of an EBV-related lymphoma at day +58 and the second child died 180 days post transplant of gastrointestinal hemorrhage caused by GVHD. Two adult patients who had undergone autologous transplantation died from disease progression, on days +45 and +60 after transplantation, respectively. At the time of evaluation with a median follow-up of 18 months, 20 patients are alive. Of four patients with Hurler's syndrome, one has about 30% donor chimerism, the second child was retransplanted using melphalan and cyclophosphamide due to rejection, and the other two are fully chimeric. The children who had a low grade of chimerism had also lower exposure to busulphan expressed as the AUC compared with the other two. The children with AML, ALL, CML and MDS are in complete remission, six are fully chimeric and two are mixed chimeras. The children transplanted for FHL, SCID, Wiskott-Aldrich syndrome and sickle cell disease are alive, well and three of them are fully chimeric. Four of six adult patients are alive, well and fully chimeric.
Toxicity
Liposomal busulphan was well tolerated; none of the patients died of regimen-related toxicity. One patient experienced mild VOD with a maximum bilirubin of 58 mol/l, ascites and increase in weight. This patient (Ch1) received 2.5 mg/kg ϫ 2 because of her aggressive disease. Her AUC was 12 879 and 12 076 ng/ml ϫ h for the first and last dose, respectively. One child (Ch17) with AML had moderate grade VOD with a maximum bilirubin of 111 mol/l, increase in weight and hepatomegaly (AUCs for the first and last dose were 14 324 and 9057 ng/ml ϫ h, respectively). Moreover, two children had elevated serum bilirubins but did not fulfill the criteria for VOD. Ultrasound examination did not show any change in liver blood flow. Both of these patients (CMML) had received additional melphalan as a part of their conditioning. Six patients developed grade II mucositis. Two of these patients required additional parenteral nutritional support. Nausea and vomiting were seen in the patient who received 2.6 mg/kg twice a day; otherwise no nausea or vomiting occurred. All patients received clonazepam as prophylaxis and none of the patients experienced seizures or other neurological toxicities. No renal or bladder toxicities were observed.
Pharmacokinetic analysis
Data from the PK analysis are summarized in Table 3 . Figures 1 and 2 show examples of the plasma concentrations over the time curve in one adult and one child patient after the first and last dose.
Area under concentration vs time curve
The AUC was measured after the first and last dose in all 24 patients (fourth dose in three and eighth dose in 21). The mean AUC (corrected for 2 mg/kg) in children was 9381 ng/ml ϫ h (s.
No significant difference was observed between the first and the last dose in either children or adults. The AUC corrected for 2 mg/kg was significantly (P Ͻ 0.01) higher in adults compared to children after the first and last dose.
Maximum concentration (Cmax)
The calculated Cmax in children ranged from 1261 to 3277 ng/ml for the first dose with a mean of 2451 ng/ml (s.d. 494 ng/ml) and from 894 to 3505 ng/ml with a mean of 2253 ng/ml (s.d. 635 ng/ml) for the last dose. The calculated Cmax in adult patients ranged from 1913 to 3517 ng/ml with the mean of 2536 ng/ml (s.d. 607 ng/ml) for the first dose and from 2049 to 3090 ng/ml with the mean of 2732 ng/ml (s.d. 361 ng/ml) for the last dose. There were no significant differences between the first and last dose in either children or adults and no difference was found comparing children and adults.
Distribution volume, clearance and elimination half-life
In children, the calculated distribution volume was 0.68 l/kg (s.d. 0.16 l/kg) after the first dose which was not significantly different from that calculated after the last dose (mean 0.73 and s.d. 0.18 l/kg). In adult patients the distribution volume was 0.55 l/kg (s.d. 0.13 l/kg) for the first dose and 0.59 l/kg (s.d. 0.06 l/kg) for the last dose. No significant difference between the first and last dose was observed in adults. No significant correlation between distribution volume and age was found after the first dose ( Figure 3 ). However, a tendency (P = 0.07) towards correlation between the distribution volume and age was observed after the last dose. A similar tendency (P = 0.07) was observed when children were compared with adults ( Table 3) .
The clearance calculated per kg body weight after the first dose in children did not differ from that calculated after the last dose 3.61 ml/min/kg (s.d. 0.62 ml/min/kg) and 3.79 ml/min/kg (s.d. 0.63 ml/min/kg), respectively. No differ-837 Table 3 Pharmacokinetic data for adults and children after the first and last dose ence was observed in adults between the first and last dose 2.40 ml/min/kg (s.d. 0.29 ml/min/kg) and 2.33 ml/min/kg (s.d. 0.22 ml/min/kg), respectively. However, clearance was significantly (P Ͻ 0.001) higher in children compared to adults after both the first and last dose. There was significant correlation between age and clearance as shown in Figure 
Figure 3
The correlation between distribution volume (Vd) corrected for body weight (kg) and age after the first dose. The solid line is the regression line. The correlation between distribution volume corrected for body weight and age after the last dose was (Vd = 0.74 + 0.003 ϫ age, r = 0.376, P = 0.07).
surface area, no significant difference was found between adults and children either after the first dose (85.3 and 92.6 ml/min/m 2 , respectively) or after the last dose (91.3 and 98.9 ml/min/m 2 , respectively). The regression analysis did not show any correlation between age and clearance corrected for body surface area ( Figure 5 ).
Elimination half-lives for children after the first and last dose (mean 2.59, s.d. 0.54 h and mean 2.72, s.d. 0.59 h, respectively) showed no significant difference. The elimination half-lives in children after both the first and last dose were significantly shorter compared to that observed in adults (mean 3.35, s.d. 0.44 h and mean 3.61, s.d. 0.74 h, respectively).
Discussion
Treatment with busulphan as a part of the myeloablative regimen prior to stem cell transplantation is still not optimal Bone Marrow Transplantation 
Figure 5
The relationship between clearance (Cl) corrected for body surface area (m 2 ) and age after the first dose. The solid line is the regression line. The correlation between clearance corrected for body surface and age after the last dose was (Cl = 84.2 + 0.19 ϫ age, r = 0.27, P = 0.19).
due to the wide inter-patient variability in pharmacokinetics in combination with the narrow therapeutic window of busulphan. A suboptimal dosage of busulphan expressed as low AUC after oral administration correlated with minimal toxicity in children and both graft rejection and relapse in adults. 29, 30 On the other hand, high exposure to busuphan during conditioning has been correlated with VOD, interstitial pneumonia and CNS toxicity. [31] [32] [33] High plasma concentrations of busulphan also correlated with transplantation-related mortality occurring before day 100 post transplant. 34 In a randomized study, busulphan compared to total body irradiation was found to be associated with an increased risk of hemorrhagic cystitis, VOD, obstructive bronchiolitis, alopecia and chronic GVHD. 35 To optimize treatment with busulphan and to minimize its toxicity during high-dose therapy, many investigators have suggested therapeutic monitoring using limited sampling models followed by dose adjustment. 9, 17, 36, 37 However, the usefulness of this strategy is limited due to the restricted possibility of performing sample analysis, losses of the drug through emesis and/or the irregular and slow absorption reported in some patients. Another alternative is to use an intravenous form of the drug. Recently, four new formulations of intravenous busulphan have been reported. Two of these formulations were based on dissolving busulphan in organic solvents dimethyl sulfoxide (DMSO) and dimethylacetamide (DMA). 21, 23 However, organic solvents have their own toxicities and may increase risk of adverse effects of the conditioning regimen. [38] [39] [40] Two other formulations based on lipid transporter system, ie microcrystalline and liposomes have been reported. 22, 24 Lipid transporter systems are prepared from lipids closely related to those naturally occurring in the body. 41 Moreover, a liposomal vehicle offers the possibility of selective targeting based on size, composition, and surface charge of the liposomes. 42 In the present study, we report the pharmacokinetics, toxicity and the clinical outcome using a conditioning regimen containing liposomal busulphan given to children and adults. Moreover, we report for the first time data showing the age-dependent pharmacokinetics of intravenous busulphan.
The inter-patient variation in drug exposure expressed as AUC after the intravenous administration of liposomal busulphan was low in adult patients (11% and 6% after first and last dose, respectively). These results are in agreement with previously reported results (10-29%) after intravenous administration of busulphan in adults. [21] [22] [23] This may reduce drug-related toxicity by decreasing the wide inter-patient variability. The mean AUC obtained in adult patients after a dose of 0.9 mg/kg was 5890 ng/ml ϫ h. This AUC corrected to 1 mg/kg is equivalent to that reported by Andersson et al, 21 Hassan et al 20 and Olavarria et al 22 who reported an AUC of 6100-6500 ng/ml ϫ h after an intravenous dose of different intravenous formulations of busulphan. [20] [21] [22] However, Schuler et al 23 reported an AUC of 9800 ng/ml ϫ h after an intravenous dose equal to 1 mg/kg busulphan dissolved in DMSO.
Children showed about 50% higher clearance compared to adults. Busulphan clearance was age dependent after the intravenous administration of liposomal busulphan ( Figure  4) . The difference in clearance between children and adults is equal to that observed when low-dose busulphan was given intravenously in a mixture of organic solvents (0.11 and 0.03 mg/kg for children and adults, respectively) as was reported previously. 15 Similar clearance was found after the administration of a single low dose of liposomal busulphan in children and adults (3.12 ml/kg/min and 2.86 ml/kg/min, respectively). 20 Andersson et al 21 have found that clearance in adult patients was 2.5 ml/kg/min using busulphan dissolved in DMA while Schuler et al 23 have found a lower clearance of 1.8 ml/kg/min in adult patients treated with intravenous busulphan dissolved in DMSO. However No difference between adults and children was found after the first dose or the last dose, when the clearance was corrected for body surface rather than body weight (Table  3) and no correlation between clearance corrected for body surface area and age was found ( Figure 5 ). Busulphan was shown to be highly trapped and metabolized in the liver. 43 A possible explanation for the difference observed between adults and children when the drug is dosed per kg body weight after intravenous administration is the difference in liver volume. Two studies have shown that liver volume is about 50% higher in children compared to adults when the hepatic mass is corrected for body weight. 44, 45 However, no difference was found when hepatic mass was corrected for body surface. Evans et al 46 demonstrated a decrease in liver volume expressed as ml/kg with increasing age, and no age-dependent difference was found when the liver volume was corrected for body surface. Recently, the higher clearance observed in children after oral administration of busulphan was explained by their superior ability to metabolize the drug through conjugation with liver glutathione during the first pass effect compared to adults. Moreover, it was shown that glutathione S-transferases level was higher in younger children. 18, 19 The distribution volume observed in the present study showed a tendency to be higher in children compared to adults (about 0.70 and 0.55 l/kg, respectively). These results are in agreement with results published previously by several investigators including our group after both oral and intravenous administration. 11, 12, 15, 21 However, in our study of the pharmacokinetics of liposomal busulphan using a single low dose, we could not observe any difference in distribution volume between adults and children. 20 This is probably due to the fact that the children included in the present study were younger. Distribution volumes of busulphan correspond directly to body water. Busulphan seems to be distributed to body water despite its lipophilic character, similar to other drugs with a low molecular weight.
We found a significant difference in elimination halflives between adults and children for both the first and last dose. However, no difference in elimination half-lives between children and adults was reported in our study of low-dose liposomal busulphan. 20 Similar to the distribution volume this is probably due to the difference in age of children included in these studies. The elimination half-lives for children were in agreement with several previous reports but in contrast to a study by Grochow et al 13 that reported a half-life of 1.5 h in children. The elimination half-lives in adults were within 1 s.d. of those reported by other investigators after the administration of high doses of intravenous busulphan. [21] [22] [23] Despite the fact that many liposomal drug formulations are trapped in the liver and spleen, the pharmacokinetics of liposomal busulphan do not differ from those seen after oral busulphan, which is most probably due to the small size of the liposomes as was described in our previous studies.
A low rate of toxicity was observed in the present study, despite higher doses of busulphan given to younger children. Nausea and vomiting were seen in one child, who received 2.6 mg/kg twice a day. This patient developed mild VOD that was self-limiting and did not require any treatment. Another patient experienced a moderate grade of VOD that resolved after defibrotide and intensive care. The AUCs obtained in both patients were in close agreement with those reported by Slattery et al. 29 Grochow et al 32 had defined an AUC of 6158 ng/ml ϫ h as an AUC associated with an increase risk for VOD. However, Shaw et al 12 have reported a five-fold higher AUC when busulphan was Bone Marrow Transplantation administered as one single daily dose (150 mg/m 2 ) without increasing the incidence of VOD. Schuler et al 37 could not establish any correlation between AUC and the occurrence of VOD. During conventional treatment with 1 mg/kg four times daily for 4 days, the steady state is reached after three doses. The liver is exposed continuously to busulphan with a minimum concentration of 400-650 ng/ml during 4 days depending on bioavailability. Since busulphan is known to be metabolized through GSH, continuous exposure of the liver to busulphan may decrease GSH and glutathione-Stransferases and subsequently decrease the protection by GSH and thereby increase the damage to the liver. 18, 19, 43 The two patients who experienced VOD were both heavily pretreated for their disease. With the exception of a small number of patients with mucositis (20%) grade II, no other organ toxicity was observed. Thus, the present formulation of busulphan was well tolerated and the toxicity profile acceptable.
Based on the present and previously published results, it is clear that busulphan pharmacokinetics are age dependent. Busulphan is one of the very few anticancer drugs for which the body weight is still the basis of dosage. However, the current data and data presented by Vassal et al 9 and Yeager et al 10 showed that the difference between adults and children was not significant when the clearance was normalized to body surface area as opposed to body weight. Vassal et al have recommended an oral dose of 37.5 mg/m 2 /day, Yeager et al suggested 38.9 mg/m 2 /day. In both studies busulphan was given four times daily. AUCs obtained in young children were equal to those seen in adults receiving 1 mg/kg four times a day. Shaw et al were able to administer busulphan as one single daily dose of 150 mg/m 2 . 12 The systemic exposure expressed as AUC observed after single-dose administration was about fourfold higher than that reported by Vassal and Yeager showing the linearity of busulphan kinetics. 9, 10 An adjustment of the dosage to body surface area will increase the given dose to young children by about 35%. In the present study the AUC obtained after an intravenous dose of 1 mg/kg was 30% lower in children compared to adults, indicating that a dosage based on body surface area should be used. An increased dosage in children will increase systemic and marrow exposure to busulphan.
Recently, Andersson et al 21 reported an AUC of 4900 ng/ml ϫ h in adults after an i.v. dose of 0.8 mg/kg. Olavarria et al 22 found that a dose of 1 mg/kg i.v. busulphan in adults resulted in a mean AUC of 6300 ng/ml ϫ h. 22 In the present study a mean AUC of 6100 ng/ml ϫ h was obtained after the administration of 0.9 mg/kg to adult patients. However, the administration of 1.1 mg/kg to children resulted in a mean AUC of 5100 ng/ml ϫ h, which is about 20% lower than that seen in adults. The administration of 0.8 mg/kg to adults will reduce the AUC to approximately 5500 ng/ml ϫ h. Thus, a dose of 0.8 mg/kg 4 times a day for 4 days in adults is equal to a total dose of 500 mg/m 2 . For children, a dose of 500 mg/m 2 will increase the dose by about 35-50%, which is equal to the difference observed in clearance between adults and children. The total myeloablative AUC over the conditioning regimen (based on 500 mg/m 2 of intravenous busulphan) is 88 000 ng/ml ϫ h. This is in close agreement with our recent study which showed that busulphan substantially inhibited colony formation in vitro using myeloid cell lines (P39 and K562) at AUC about 100 000 ng/ml ϫ h. 47 In conclusion, this is the first study of intravenous liposomal busulphan in very young children and adults. Liposomal busulphan is a suitable formulation for intravenous administration in high doses prior to SCT. The new formulation was well tolerated, showed a good myeloablative effect and low toxicity profile. Age-dependent pharmacokinetics after the administration of intravenous liposomal busulphan were observed. An optimal dose of 500 mg/m 2 to children will allow a mean systemic exposure equal to that seen in adults, without increasing the risk of serious and/or life-threatening toxicity.
